{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bacterial-vaginosis/management/women-who-are-pregnant/","result":{"pageContext":{"chapter":{"id":"e17bea46-46ca-5a5a-8f23-6d2541ef18b2","slug":"women-who-are-pregnant","fullItemName":"Scenario: Women who are pregnant","depth":2,"htmlHeader":"<!-- begin field ae2cc223-b90a-4b36-b8e2-f19fabf7f5f6 --><h2>Scenario: Bacterial vaginosis in women who are pregnant</h2><!-- end field ae2cc223-b90a-4b36-b8e2-f19fabf7f5f6 -->","summary":"Covers the management of suspected BV in women who are pregnant.","htmlStringContent":"<!-- begin item 33a908f8-e45c-41b1-ab36-1fdfdc2fbc53 --><!-- begin field a80865ad-2cd9-42e3-a61b-acbc015a9466 --><p>From age 12 years onwards (Female).</p><!-- end field a80865ad-2cd9-42e3-a61b-acbc015a9466 --><!-- end item 33a908f8-e45c-41b1-ab36-1fdfdc2fbc53 -->","topic":{"id":"865cdea2-9043-57ef-8b25-031205cdd37d","topicId":"afc41d7e-87dd-41b7-bbc7-b86b9168703c","topicName":"Bacterial vaginosis","slug":"bacterial-vaginosis","lastRevised":"Last revised in October 2018","chapters":[{"id":"f7fe1c4f-d424-53b7-9e1d-2e724534b550","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ff6b3e14-7f5b-50db-8eee-ad227bf399c7","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9d2f35ec-215f-5ee1-b407-2c5b68e931b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"06809c66-f539-5454-a18a-ff951a80494b","slug":"changes","fullItemName":"Changes"},{"id":"0872ed37-dd2a-58ae-ba58-ecd7dd9c964e","slug":"update","fullItemName":"Update"}]},{"id":"b96f10d4-f421-527a-bcaf-8e5e46afb0b5","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"7b27492c-f7b2-5bdf-8be5-596f1ad99050","slug":"goals","fullItemName":"Goals"},{"id":"8b94b860-815d-522b-b4fe-461ef978443a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"b1dc3d72-ac27-5757-be13-e2015daa0798","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8cef0513-bbd8-5919-961e-a28c7cfdd421","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7bc7f747-27e8-5daa-9d10-380bdcd0f2e2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e58af854-9d1b-51ce-a49a-83df8540a21a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d6cf6c66-7d92-5d41-933f-a9a879fa36d4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ebdd3d77-69b1-523d-a4ac-4de1bd53fcfe","slug":"definition","fullItemName":"Definition"},{"id":"7f17b28f-8990-5777-98b2-0b0a488d883f","slug":"contributing-factors","fullItemName":"Contributing factors"},{"id":"276cab7f-4264-59d9-8986-e8de8d64e45e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9a592036-9b11-587b-8576-77aac8d2b2ef","slug":"complications","fullItemName":"Complications"}]},{"id":"a011fb71-c488-53bd-b5ca-10e92c77583a","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b250f8fd-847f-5844-a2d6-32014c81a438","slug":"assessment","fullItemName":"Assessment"},{"id":"e655909b-34b2-55ce-8897-68a2131e1a0c","slug":"examination-investigations","fullItemName":"Examination and investigations"},{"id":"5cc72fff-2222-558d-815e-907a5a25c2ef","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","fullItemName":"Management","slug":"management","subChapters":[{"id":"c43aecb1-cb55-5433-a0ce-81481bc43060","slug":"women-who-are-not-pregnant","fullItemName":"Scenario: Women who are not pregnant"},{"id":"e17bea46-46ca-5a5a-8f23-6d2541ef18b2","slug":"women-who-are-pregnant","fullItemName":"Scenario: Women who are pregnant"}]},{"id":"ff8ddbda-8b29-5d43-ad60-5aeb14b120d3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"39735e82-4c9f-5aa2-97c7-1496f80b7c1f","slug":"oral-metronidazole","fullItemName":"Oral metronidazole"},{"id":"5eef68f3-35a3-5708-a789-014713e8af64","slug":"intravaginal-metronidazole","fullItemName":"Intravaginal metronidazole"},{"id":"ecf84ab7-5f32-5135-a8c2-b302e217480a","slug":"intravaginal-clindamycin","fullItemName":"Intravaginal clindamycin"}]},{"id":"dbca4e81-4cb5-5161-95af-5aed06ab1909","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bab503ee-9268-578a-957b-b6f29998ba50","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a1542e98-52d3-5650-8f50-017cdafb6bb1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dddaaa3b-0dea-5b97-a24a-18f6f861a9b4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"305419c2-e2ba-51d7-b38f-9d98fdb980ed","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b64a9957-d6e0-5d40-9465-e092bfde8548","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"748d8b76-5aee-5fe6-898a-43bbffd5751b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efc1492f-d327-53ae-b257-f0f17e740c27","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0ae8498b-179a-5f9f-8ece-c5004a1ed196","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"41567151-80cf-59a3-9698-e44b1065dc7d","slug":"managing-bacterial-vaginosis","fullItemName":"Managing bacterial vaginosis","depth":3,"htmlHeader":"<!-- begin field 475b841d-846b-474b-8fa6-b1b1dbd6b7d5 --><h3>How should I manage a woman with bacterial vaginosis who is pregnant?</h3><!-- end field 475b841d-846b-474b-8fa6-b1b1dbd6b7d5 -->","summary":null,"htmlStringContent":"<!-- begin item 4d954e95-284f-4333-9937-a3b398af7832 --><!-- begin field 5bdfe07d-0cbc-4abc-9d56-85021266e7ee --><p><strong>Do not offer pregnant women routine screening for bacterial vaginosis (BV). However, if a pregnant woman is incidentally found to have BV, manage as follows:</strong></p><ul><li><strong>If the woman is asymptomatic,</strong> discuss with the woman's obstetrician whether treatment is appropriate.</li><li><strong>If the woman is symptomatic:</strong><ul><li>Advise that, where possible, she should reduce exposure to <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/background-information/contributing-factors/\"> contributing factors</a>, such as vaginal douching and the use of antiseptics, bubble baths, or shampoos in the bath.</li><li>Prescribe oral metronidazole 400 mg twice a day for 5 to 7 days. <ul><li>High-dose regimens (single oral dose of 2 g) are not recommended during pregnancy.</li><li>See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/prescribing-information/oral-metronidazole/\">Oral metronidazole</a> for prescribing information on this treatment, including contraindications and cautions, adverse effects, and possible drug interactions. </li></ul></li><li>If the woman prefers topical treatment or cannot tolerate oral metronidazole:<ul><li>Prescribe intravaginal metronidazole gel 0.75% once a day for 5 days (off-label for women aged younger than 18 years) or intravaginal clindamycin cream 2% once a day for 7 days.</li><li>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/prescribing-information/intravaginal-metronidazole/\">intravaginal metronidazole</a> and <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/prescribing-information/intravaginal-clindamycin/\">Intravaginal clindamycin</a> for prescribing information on these treatments, including contraindications and cautions, adverse effects, and possible drug interactions. </li></ul></li><li>Oral clindamycin is an alternative but is less preferred.</li><li>Repeat testing after 1 month (and offer further treatment) if the women is still symptomatic. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/management/women-who-are-pregnant/#managing-persistent-or-recurrent-symptoms\">Managing persistent or recurrent symptoms</a> for more information.</li></ul></li></ul><!-- end field 5bdfe07d-0cbc-4abc-9d56-85021266e7ee --><!-- end item 4d954e95-284f-4333-9937-a3b398af7832 -->","subChapters":[{"id":"82c143fe-6385-56e3-a3d7-93fc81bbdfc6","slug":"basis-for-recommendation-0f5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 93ed02f4-b23d-48f0-8174-5815c668c1aa --><h4>Basis for recommendation</h4><!-- end field 93ed02f4-b23d-48f0-8174-5815c668c1aa -->","summary":null,"htmlStringContent":"<!-- begin item 0f520fa2-4710-4856-89e3-120087544aad --><!-- begin field a12aa888-ff91-46b9-8daf-7605edcc063e --><p>These recommendations are largely based on the <em>UK national guideline for the management of bacterial vaginosis </em>published by the British Association for Sexual Health and HIV (BASHH) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BASHH, 2012</a>], <em>Sexually Transmitted Infections in Primary Care 2013 (RCGP/BASHH) </em>published on behalf of the Royal College of General Practitioners (RCGP) and BASHH [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Lazaro, 2013</a>], <em>Management of Management and laboratory diagnosis of Abnormal Vaginal Discharge: Quick Reference Guide for Primary Care </em>published by Public Health England (PHE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">PHE, 2013</a>], and the <em>2018 European (IUSTI/WHO) Guideline on the Management of Vaginal Discharge </em>published on behalf of<em> </em>the International Union against Sexually Transmitted Infections (IUSTI) and the World Health Organization (WHO)<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>].</p><h5>Screening for bacterial vaginosis (BV) in asymptomatic pregnant women</h5><ul><li>Experts do not recommend routine screening for BV in pregnant women because the evidence suggests that identification and treatment of asymptomatic BV does not lower the risk for pre-term birth and other adverse reproductive outcomes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Lazaro, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">NICE, 2017</a>].<ul><li>However, the British HIV Association recommends screening for BV in pregnant women who are infected with HIV because there is an increased risk of mother-to-child transmission of HIV-1 in the presence of BV [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">de Ruiter et al, 2008</a>].</li></ul></li><li>The recommendation that the management of asymptomatic pregnant women should be considered on an individual basis after discussion with the woman's obstetrician is pragmatic, as evidence on the treatment of BV to prevent adverse outcomes in pregnancy is conflicting.<ul><li>A Cochrane systematic review (search date: to May 2012) assessed the effects of antibiotic treatment of BV in pregnant women of any age, at any stage of pregnancy, and regardless of method of diagnosis (detected because of symptoms or asymptomatic as part of a screening programme) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Brocklehurst, 2013</a>]. The review included 21 trials of good quality, involving 7847 women diagnosed with BV or intermediate vaginal flora.</li><li>The evidence showed that antibiotic treatment was effective at eradicating BV during pregnancy, and reduced the risk of late miscarriage; however, the overall risk of pre-term birth was not significantly reduced. </li><li>The authors of the Cochrane systematic review concluded that the review provides little evidence that screening and treating all pregnant women with BV will prevent preterm birth and its consequences.</li></ul></li><li>The IUSTI/WHO guideline states that positive direct microscopy with or without symptoms in some pregnant women (those with a history of prior idiopathic preterm birth or second trimester loss) is an indication for treatment of BV<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>]. </li></ul><h5>Antibiotic choices</h5><ul><li>A small trial (n = 156 women) included in a Cochrane systematic review (search date: to May 2012) compared metronidazole with clindamycin, both oral and vaginal, in the treatment of BV in pregnancy and found no significant differences for any of the pre-specified primary outcomes, including [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Brocklehurst, 2013</a>]:<ul><li>Failure to eradicate BV on examination (failure to achieve ’microbiological cure’).</li><li>Incidence of pregnancy loss up to 24 weeks’ gestation (late miscarriage).</li><li>Perinatal death including stillbirth after 24 weeks’ gestation and neonatal death, up to 28 days after birth.</li><li>Neonatal sepsis (defined as definite symptoms or positive cultures from a sterile site - positive culture of gastric aspirates alone will not be sufficient).</li><li>Birth less than 37, 34, and 32 weeks’ gestation.</li><li>Incidence of low birthweight (however defined).</li><li>Birthweight (not a prespecified outcome).</li><li>Prolongation of gestation age (not a prespecified outcome).</li><li>Adverse effects sufficient to stop or change treatment.</li><li>Other adverse effects not sufficient to stop or change treatment.</li><li>Statistically significant differences were seen for the outcomes of prolongation of gestational age (days); however, these represent relatively small differences in the clinical setting.</li><li>Different frequency of dosing of antibiotics was assessed in one small trial and showed no significant difference for any outcome assessed.</li></ul></li><li>Metronidazole is licensed for the prophylaxis and treatment of infections in which anaerobic bacteria have been identified or are suspected to be the cause [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2017</a>], such as BV. It is a well established treatment and usually well tolerated. The UK teratology information service advise that [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">UKTIS, 2017</a>]:<ul><li>Available data, which are almost exclusively based on oral exposure, do not indicate an increased risk of congenital malformation, low birth weight, intrauterine death, or neonatal complications with metronidazole use in human pregnancy, and recent studies have not found an association between metronidazole use and preterm delivery. Data on spontaneous abortion are conflicting: a cohort study found no significant increase in risk, but a nested case control analysis suggests a possible association with metronidazole treatment in pregnancy.</li><li>Where possible, the results of culture and sensitivity tests should be available before making a treatment choice in accordance with local prescribing guidelines.</li></ul></li><li>The manufacturer of intravaginal clindamycin recommends that it should be used in pregnancy only if clearly needed [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2018</a>], and the British National Formulary (BNF) states that clindamycin is not known to be harmful in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">BNF 75, 2018</a>].</li><li>Oral clindamycin is not widely recommended in primary care because of an increased risk of pseudomembranous colitis associated with its use.</li><li>The safety of tinidazole in pregnant women has not been well evaluated, and the manufacturer states that it is contraindicated during the first trimester of pregnancy and in nursing mothers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">ABPI, 2016</a>].</li></ul><h5>Test of cure </h5><ul><li>This recommendation is based on the IUSTI/WHO guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bacterial-vaginosis/references/\">Sherrard, 2018</a>], which states that if treatment is prescribed in pregnancy to reduce the risk of preterm birth, a repeat test should be made after one month and further treatment offered if BV has recurred.</li></ul><!-- end field a12aa888-ff91-46b9-8daf-7605edcc063e --><!-- end item 0f520fa2-4710-4856-89e3-120087544aad -->","subChapters":[]}]},{"id":"77e0bbfc-e8be-591b-98cb-c08829adccee","slug":"managing-persistent-or-recurrent-symptoms","fullItemName":"Managing persistent or recurrent symptoms","depth":3,"htmlHeader":"<!-- begin field d73b10d5-1f52-4c7b-a77b-a77700b6e0c5 --><h3>How should I manage a woman with persistent or recurrent symptoms during pregnancy?</h3><!-- end field d73b10d5-1f52-4c7b-a77b-a77700b6e0c5 -->","summary":null,"htmlStringContent":"<!-- begin item 23013b4f-cf83-489f-8913-a77700b6de86 --><!-- begin field c7bfcbab-e13e-43c9-a49b-a77700b6e0c5 --><ul><li><strong>If symptoms persist or recur after initial treatment:</strong><ul><li>Check that the <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/management/women-who-are-pregnant/#managing-bacterial-vaginosis\">initial treatment</a> was adhered to.</li><li>Reconsider the <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/diagnosis/examination-investigations/\">diagnosis</a>. Perform a speculum examination and take swabs for culture. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/diagnosis/examination-investigations/\">Examination and investigations</a> for more information.</li><li>Enquire about continued exposure to <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/background-information/contributing-factors/\"> contributing factors</a>, such as vaginal douching and the use of antiseptics, bubble baths, or shampoos in the bath.</li><li>If initial treatment was adhered to, the diagnosis is confirmed, and contributing factors have been avoided (where possible), ensure that the current episode is adequately managed. Consider one of the following options:<ul><li>Prescribe an <a class=\"topic-reference internal-reference\" href=\"/topics/bacterial-vaginosis/management/women-who-are-pregnant/#managing-bacterial-vaginosis\">alternative treatment</a>, for example oral treatment if intravaginal treatment was previously used.</li><li>Seek advice regarding further treatment from the woman's obstetrician or a genito-urinary physician.</li></ul></li></ul></li></ul><!-- end field c7bfcbab-e13e-43c9-a49b-a77700b6e0c5 --><!-- end item 23013b4f-cf83-489f-8913-a77700b6de86 -->","subChapters":[{"id":"7cda9e33-7072-55d2-9a14-74dfb4d4ac98","slug":"basis-for-recommendation-fc5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 5c548297-0ecd-4ba5-b361-a77700b6e0ca --><h4>Basis for recommendation</h4><!-- end field 5c548297-0ecd-4ba5-b361-a77700b6e0ca -->","summary":null,"htmlStringContent":"<!-- begin item fc59ebdf-fb55-47f7-855b-a77700b6e0ca --><!-- begin field b5a7b9a1-2642-4134-bd9d-a77700b6e0ca --><p>CKS found no evidence regarding treatment options if initial treatment is unsuccessful in a woman who is pregnant. These recommendations are based on what CKS considers to be good clinical practice. Discussion with the woman's obstetrician or a genito-urinary physician is recommended to avoid exposing the woman to repeated courses of antibiotics.</p><!-- end field b5a7b9a1-2642-4134-bd9d-a77700b6e0ca --><!-- end item fc59ebdf-fb55-47f7-855b-a77700b6e0ca -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}